Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  TESARO Inc    TSRO

TESARO INC (TSRO)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/18/2018 04/19/2018 04/20/2018 04/23/2018 04/24/2018 Date
54.53(c) 52.21(c) 51.58(c) 51.98(c) 52.3 Last
545 055 909 965 641 252 457 496 70 175 Volume
-0.69% -4.25% -1.21% +0.78% +0.62% Change
More quotes
Financials (USD)
Sales 2018 311 M
EBIT 2018 -493 M
Net income 2018 -516 M
Finance 2018 248 M
Yield 2018 -
Sales 2019 530 M
EBIT 2019 -346 M
Net income 2019 -342 M
Finance 2019 91,6 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 8,28x
EV / Sales2019 5,16x
Capitalization 2 827 M
More Financials
Company
TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products.It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib.The company was founded by Leon Moulder, Jr., Mary Lynne Hedley,... 
More about the company
Surperformance© ratings of TESARO Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on TESARO INC
01:01pTESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA®
GL
04/20TESARO : to Receive 2018 Partnership Award at CancerCare Gala
AQ
04/19TESARO : to Announce First-Quarter 2018 Financial Results on May 3, 2018
AQ
04/19TESARO : Summarizes TSR-042 Clinical Data Presented at AACR
AQ
04/16TESARO : Summarizes TSR-042 Clinical Data Presented at AACR
AQ
04/16TESARO : and Medison Enter Into Exclusive Distribution Agreement to Commercializ..
AQ
04/11TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercial..
GL
04/11TESARO : and Medison Enter Into Exclusive Distribution Agreement to Commercializ..
GL
03/29TESARO : Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinica..
AQ
03/27TESARO : Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinica..
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
01:06p$TSRO TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA®.. 
01:01pTESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA®  
01:00p$TSRO Announces Positive Top-Line Results From Quadra Trial of ZEJULA
4
04/23Tesaro $TSRO Given a $120.00 Price Target at Lake Street Capital  
04/22Tesaro $TSRO Rating Lowered to Strong Sell at BidaskClub  
More tweets
Qtime:68
News from SeekingAlpha
04/13TESARO : Time To Buy 
04/11TESARO establishes Zejula distribution in Israel 
04/11BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Novartis's Gene Therapy Catch, AstraZenec.. 
04/08READER INQUIRY : Does Clovis Oncology's Expansion Approval Make It A Buy? 
04/06Clovis Oncology +3.8% on approved expansion for Rubraca 
Chart TESARO INC
Duration : Period :
TESARO Inc Technical Analysis Chart | TSRO | US8815691071 | 4-Traders
Technical analysis trends TESARO INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 94,6 $
Spread / Average Target 82%
EPS Revisions
Managers
NameTitle
Leon O. Moulder Chief Executive Officer & Director
Mary Lynne Hedley President, Chief Operating Officer & Director
David M. Mott Chairman
Timothy R. Pearson Chief Financial & Accounting Officer, Executive VP
Martin H. Huber Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
TESARO INC-37.28%2 827
GILEAD SCIENCES3.31%96 094
VERTEX PHARMACEUTICALS5.89%40 153
REGENERON PHARMACEUTICALS-15.95%33 844
GENMAB23.13%12 797
BEIGENE LTD (ADR)71.91%8 998